Nalaganje...
Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
BACKGROUND: Long-acting muscarinic antagonist/long-acting β(2)-agonist (LAMA/LABA) provide greater improvements in lung function and symptoms than inhaled corticosteroid (ICS)/LABA in patients with chronic obstructive pulmonary disease (COPD). This study evaluated symptom burden and Global Initiativ...
Shranjeno v:
| izdano v: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7605915/ https://ncbi.nlm.nih.gov/pubmed/33149569 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S265037 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|